Asthma Model

Introduction

Asthma is a chronic inflammatory airway disease involving various cell types (such as eosinophils, mast cells, and T lymphocytes) and their cellular components, characterized by heterogeneity and airway hyperresponsiveness. Its core pathological manifestations include airway inflammation, airway remodeling, and variable airflow limitation. Clinically, it is characterized by recurrent episodes of wheezing, chest tightness, and coughing, which often worsen at night or in the early morning. Most patients can achieve relief with treatment.

Disease models

High-quality asthma disease models serve as excellent tools for drug evaluation. Common modeling approaches involve using house dust mite (HDM) extract, ovalbumin (OVA), and other agents to establish mouse models of asthma. SMOC has independently developed a variety of asthma mouse models, validated across different strains (C57BL/6, hIL4/hIL4R mice, BALB/c, etc.), which can be used for the efficacy evaluation of asthma therapeutic drugs.

OVA induced asthma model in BALB/c mice



image.png

image.png

Fig.1 OVA induced asthma model in BALB/c mice.(A) Body weight (B) Body weight change. (*P<0.05, **P<0.01 Vs Group2)

image.png


Fig.2 OVA induced asthma model in BALB/c mice.(A) Inflammatory cell number in BALF. (B) Eosinophils in BALF. (C) Eosinophils percentage in inflammatory cell. (D) Serum total IgE concentration.


image.png

Fig.3 OVA induced asthma model in BALB/c mice. (A) Lung H&E and PAS stain(B) Inflammatory cell infiltration score (C) Bronchial score.

HDM induced asthma model in hIL4/hIL4R mice

image.png

image.png

Fig.1 Body weight of HDM induced hIL4/hIL4R mice asthma model (n=6, Data are presented as Mean and ± SEM).

image.png

Fig.2 HDM induced hIL4/hIL4R mice asthma model. (A) Inflammatory cell number in BALF. (B) Eosinophils in BALF. (C) Eosinophils percentage in inflammatory cell. (D) Serum total IgE concentration. (n=6, Data are presented as Mean and ± SEM.) 

image.png

Fig.3 HDM induced hIL4/hIL4R mice asthma model. (A) hIL-4 mRNA expression level. (B) mIL-8 mRNA expression level. (C) mIL-13 mRNA expression level. (D) mIL-6 mRNA expression level. (E) mIL-17a mRNA expression level.

image.png

Fig.4 HDM induced hIL-4/hIL-4R mice asthma model. (A) Representative images of H&E staining. (B) Pathology score results. (n=6, Data are presented as Mean and ± SEM.) Magnification, ×5.

image.png

Fig.5 HDM induced hIL-4/hIL-4R mice asthma model. (A) Representative images of PAS staining. (B)mucus score. (n=6, Data are presented as Mean and ± SEM.) Magnification, ×10.

HDM induced asthma model in hTSLP/hTSLPR mice

image.png

Fig1. HDM induced asthma in hTSLP/hTSLPR mice. (A) body weight (B) body weight change 

image.png

Fig 2. HDM induced asthma in hTSLP/hTSLPR mice. (A) serum mIgE (B) serum HDM mIgE

image.png

Fig3. HDM induced asthma in hTSLP/hTSLPR mice. (A) BALF mCD45 events (B) BALF Eos events (C) BALF Eos%/mCD45

image.png

Fig4. HDM induced asthma in hTSLP/hTSLPR mice. (A) pathology score (B) Representative photographs of H&E and PAS -stained lung sections


HDM induced asthma model in C57BL/6 mice

image.png

Fig 1. Body weight monitoring in an HDM-induced asthma model in C57BL/6 mice. (A) Body weight over time. (B) Percentage change in body weight relative to baseline.

image.png

Fig 2. The efficacy of DEX on the HDM-induced asthma model in C57BL/6 mice. (A) Absolute number of eosinophils in BALF. (B) Percentage of eosinophils relative to total inflammatory cells. (C) Total serum IgE concentration.

OVA and hTSLP induced asthma model in hIL4/hIL4R/hTSLP/hCRLF2 mice

image.png

Fig 1. Analysis of inflammatory cell populations in BALF. Flow cytometric quantification of inflammatory cells in BALF. (A) Percentage of macrophages. (B) Percentage of eosinophils. (C) Percentage of lymphocytes.

image.png

Fig 2. The efficacy Dupilumab and Tezepelumab on OVA+hTSLP-induced asthma model in hIL4/hIL4R/hTSLP/hCRLF2 mice. (A) Concentration of total serum IgE. (B) Concentration of OVA-specific serum IgE. (C) Relative mRNA expression of mCCL17 in lung tissue. (D) Relative mRNA expression of hIL-4 in lung tissue.

image.png

Fig 3. Comprehensive histopathological assessment of lung injury.

image.png

Fig 4. Comprehensive histopathological assessment of lung injury. (A) Inflammatory cell infiltration Score. (B) Eosinophil cell infiltration Score. (C) Bronchial Goblet Cell Hyperplasia Score. (D) Airway Basement Membrane Thickening Score. (E) Total Lung Injury Score. (F) PAS Staining Score.


OVA and hTSLP and hIL33 induced asthma model in hIL33/hTSLP/hCRLF2 mice

image.png

Fig 1. The efficacy of Itepekimab and Tezepelumab on OVA+hTSLP+hIL33-induced asthma model in hIL33/hTSLP/hCRLF2 mice. Mice were challenged with OVA and hTSLP+hIL33 and treated with Itepekimab, Tezepelumab, or a combination. (A) Body weight over time. (B) Percentage change in body weight relative to baseline.

image.png

Fig 2. Analysis of inflammatory cell populations in BALF. Flow cytometric quantification of inflammatory cells in BALF. (A) Total inflammatory cell count in BALF. (B) Percentage of lymphocytes among total inflammatory cells. (C) Absolute lymphocytes count in BALF. 

image.png

Fig 3. Analysis of inflammatory cell populations in BALF. Flow cytometric quantification of inflammatory cells in BALF. (A) Percentage of eosinophils among total inflammatory cells. (B) Absolute eosinophils count in BALF. (C) Percentage of neutrophils among total inflammatory cells. (D) Absolute neutrophils count in BALF. 

image.png

Fig 4. Analysis of inflammatory cell populations in BALF. Flow cytometric quantification of inflammatory cells in BALF. (A) Percentage of macrophage among total inflammatory cells. (B) Absolute macrophage count in BALF. (C) Percentage of DC cell among total inflammatory cells. (D) Absolute DC cell count in BALF. 

image.png

Fig 5. The efficacy of Itepekimab and Tezepelumab on OVA+hTSLP+hIL33-induced asthma model in hIL33/hTSLP/hCRLF2 mice. (A) Concentration of total serum IgE. 

image.png

Fig 6. The efficacy of Itepekimab and Tezepelumab on OVA+hTSLP+hIL33-induced asthma model in hIL33/hTSLP/hCRLF2 mice. (A) Relative mRNA expression of mIL-13 in lung tissue. (B) Relative mRNA expression of mIL-4 in lung tissue. (C) Relative mRNA expression of mIL-5 in lung tissue.

image.png

Fig 7. Comprehensive histopathological assessment of lung injury. (A) Representative photographs of H&E-stained lung sections and PAS-stained lung sections.

image.png

Fig 8. Comprehensive histopathological assessment of lung injury. (A) Inflammatory cell infiltration Score. (B) Eosinophil cell infiltration Score. (C) Bronchial Goblet Cell Hyperplasia Score. (D) Airway Basement Membrane Thickening Score. (E) Total Lung Injury Score.  (F) PAS Staining Score.


南模生物Email Back to top 点击跳转到顶部